These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 11286307

  • 41. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 42. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
    Monteiro P, Duarte AI, Gonçalves LM, Moreno A, Providência LA.
    Eur J Pharmacol; 2004 Oct 25; 503(1-3):123-8. PubMed ID: 15496306
    [Abstract] [Full Text] [Related]

  • 43. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
    Stanley WC, Sabbah HN.
    Heart Fail Rev; 2005 Dec 25; 10(4):275-9. PubMed ID: 16583175
    [No Abstract] [Full Text] [Related]

  • 44. Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors.
    Cheng JF, Chen M, Liu B, Hou Z, Arrhenius T, Nadzan AM.
    Bioorg Med Chem Lett; 2006 Feb 25; 16(3):695-700. PubMed ID: 16257202
    [Abstract] [Full Text] [Related]

  • 45. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions.
    Stanley WC, Lopaschuk GD, Hall JL, McCormack JG.
    Cardiovasc Res; 1997 Feb 25; 33(2):243-57. PubMed ID: 9074687
    [Abstract] [Full Text] [Related]

  • 46. Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the diabetic.
    Lopaschuk GD.
    Can J Cardiol; 1989 Sep 25; 5(6):315-20. PubMed ID: 2676122
    [Abstract] [Full Text] [Related]

  • 47. [Metabolic considerations in the treatment of coronary disease in diabetic patients].
    Piot C.
    Diabetes Metab; 2001 Nov 25; 27(5 Pt 2):S25-9. PubMed ID: 11910982
    [Abstract] [Full Text] [Related]

  • 48. Metabolic remodelling of the failing heart: beneficial or detrimental?
    van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ.
    Cardiovasc Res; 2009 Feb 15; 81(3):420-8. PubMed ID: 18854380
    [Abstract] [Full Text] [Related]

  • 49. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease.
    Beadle RM, Frenneaux M.
    Heart; 2010 Jun 15; 96(11):824-30. PubMed ID: 20478861
    [Abstract] [Full Text] [Related]

  • 50. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates.
    Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G.
    J Nutr Biochem; 2006 Sep 15; 17(9):571-88. PubMed ID: 16524713
    [Abstract] [Full Text] [Related]

  • 51. Myocardial metabolism: pharmacological manipulation in myocardial ischaemia.
    Mitra B, Panja M.
    J Assoc Physicians India; 2005 Jun 15; 53():552-60. PubMed ID: 16121812
    [Abstract] [Full Text] [Related]

  • 52. Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart.
    Wang P, Lloyd SG, Chatham JC.
    Circulation; 2005 Apr 26; 111(16):2066-72. PubMed ID: 15824201
    [Abstract] [Full Text] [Related]

  • 53. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
    Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS.
    J Mol Cell Cardiol; 2008 Jan 26; 44(1):201-9. PubMed ID: 17931655
    [Abstract] [Full Text] [Related]

  • 54. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G, Spoladore R, Cuko A, Palloshi A.
    Curr Clin Pharmacol; 2007 Sep 26; 2(3):190-6. PubMed ID: 18690865
    [Abstract] [Full Text] [Related]

  • 55. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies.
    Stanley WC.
    J Cardiovasc Pharmacol Ther; 2004 Sep 26; 9 Suppl 1():S31-45. PubMed ID: 15378130
    [Abstract] [Full Text] [Related]

  • 56. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L, Horowitz J, Frenneaux M.
    Eur Heart J; 2004 Apr 26; 25(8):634-41. PubMed ID: 15084367
    [Abstract] [Full Text] [Related]

  • 57. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
    Bucci M, Borra R, Någren K, Pärkkä JP, Del Ry S, Maggio R, Tuunanen H, Viljanen T, Cabiati M, Rigazio S, Taittonen M, Pagotto U, Parkkola R, Opie LH, Nuutila P, Knuuti J, Iozzo P.
    Cardiovasc Ther; 2012 Dec 26; 30(6):333-41. PubMed ID: 21884010
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS, Hill JA.
    Am J Cardiovasc Drugs; 2001 Dec 26; 1(1):23-35. PubMed ID: 14728049
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.